Zacks Research Issues Pessimistic Estimate for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities research analysts at Zacks Research reduced their Q4 2024 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a report issued on Wednesday, November 27th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $0.46 for the quarter, down from their previous forecast of $0.48. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.88 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.57 EPS, Q2 2026 earnings at $0.58 EPS and FY2026 earnings at $2.36 EPS.

Several other brokerages have also recently issued reports on CPRX. Truist Financial raised their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Citigroup raised their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and an average price target of $31.14.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $22.53 on Monday. Catalyst Pharmaceuticals has a one year low of $13.00 and a one year high of $24.27. The stock has a market capitalization of $2.69 billion, a PE ratio of 19.09, a price-to-earnings-growth ratio of 3.40 and a beta of 0.75. The business’s fifty day moving average is $21.30 and its 200 day moving average is $18.83.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. raised its position in shares of Catalyst Pharmaceuticals by 3.4% in the 3rd quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company’s stock worth $1,221,000 after acquiring an additional 1,967 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth $667,000. Hohimer Wealth Management LLC bought a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth $329,000. Vestcor Inc raised its position in shares of Catalyst Pharmaceuticals by 18.4% in the 3rd quarter. Vestcor Inc now owns 60,431 shares of the biopharmaceutical company’s stock worth $1,201,000 after acquiring an additional 9,379 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock worth $4,939,000 after acquiring an additional 140,129 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.